ArticlePloS one2022
Development of a multi-year white-nose syndrome mitigation strategy using antifungal volatile organic compounds.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Transcriptomic and Metabolomic Insights into the Inhibitory Mechanisms of Bat Cave Soil Microbial Volatiles AgainstMicroorganisms · 2026Article
- Inhibitory and synergistic effects of volatile organic compounds from bat caves againstmSystems · 2026Article
- Mechanisms of volatile organic compounds from bat cave environments againstApplied and environmental microbiology · 2025Article
- Article
- Differential Population Responses to White-Nose Syndrome Between Two Michigan Bat Hibernacula Are Not due to Differences in Host Susceptibility.Ecology and evolution · 2025Article
- Winter activity of tricolored bats in aboveground and subterranean hibernacula in the southeastern USA.Scientific reports · 2025Article
- Vulnerability of Southern Hemisphere bats to white-nose syndrome based on global analysis of fungal host specificity and cave temperatures.Conservation biology : the journal of the Society for Conservation Biology · 2025Article
- Microbiota diversity and anti-Applied and environmental microbiology · 2024Article
- Thermally unstable roosts influence winter torpor patterns in a threatened bat species.Conservation physiology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudogymnoascus destructans is a fungal pathogen responsible for a deadly disease among North American bats known as white-nose syndrome (WNS). Since detection of WNS in the United States in 2006, its rapid spread and high mortality has challenged development of treatment and prevention methods, a significant objective for wildlife management agencies. In an effort to mitigate precipitous declines in bat populations due to WNS, we have developed and implemented a multi-year mitigation strategy at Black Diamond Tunnel (BDT), Georgia, singly known as one of the most substantial winter colony sites for tricolored bats (Perimyotis subflavus), with pre-WNS abundance exceeding 5000 individuals. Our mitigation approach involved in situ treatment of bats at the colony level through aerosol distribution of antifungal volatile organic compounds (VOCs) that demonstrated an in vitro ability to inhibit P. destructans conidia germination and mycelial growth through contact-independent exposure. The VOCs evaluated have been identified from microbes inhabiting naturally-occurring fungistatic soils and endophytic fungi. These VOCs are of low toxicity to mammals and have been observed to elicit antagonism of P. destructans at low gaseous concentrations. Cumulatively, our observations resolved no detrimental impact on bat behavior or health, yet indicated a potential for attenuation of WNS related declines at BDT and demonstrated the feasibility of this novel disease management approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.